$JUNO Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Juno Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Juno Therapeutics, Inc.. Get notifications about new insider transactions in Juno Therapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 02 2016 | JUNO | Juno Therapeutics, ... | Harr Steve | See Remarks | Sell | S | 36.20 | 10,581 | 382,997 | 752,406 | 763 K to 752.4 K (-1.39 %) |
Mar 02 2016 | JUNO | Juno Therapeutics, ... | Harr Steve | See Remarks | Sell | S | 35.06 | 2,013 | 70,571 | 762,987 | 765 K to 763 K (-0.26 %) |
Mar 02 2016 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | See Remarks | Option Exercise | M | 6.36 | 54,000 | 343,440 | 893,506 | |
Mar 02 2016 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | See Remarks | Sell | S | 36.46 | 3,879 | 141,421 | 2,650,609 | 2.7 M to 2.7 M (-0.15 %) |
Mar 02 2016 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | See Remarks | Sell | S | 35.27 | 86,871 | 3,063,584 | 2,654,488 | 2.7 M to 2.7 M (-3.17 %) |
Mar 02 2016 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | See Remarks | Buy | M | 6.36 | 54,000 | 343,440 | 2,741,359 | 2.7 M to 2.7 M (+2.01 %) |
Mar 02 2016 | JUNO | Juno Therapeutics, ... | Frohlich Mark W | See Remarks | Sell | S | 36.50 | 300 | 10,950 | 919,583 | 919.9 K to 919.6 K (-0.03 %) |
Mar 02 2016 | JUNO | Juno Therapeutics, ... | Frohlich Mark W | See Remarks | Sell | S | 35.25 | 19,700 | 694,392 | 919,883 | 939.6 K to 919.9 K (-2.10 %) |
Mar 02 2016 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 41.22 | 760 | 31,327 | 894,499 | 895.3 K to 894.5 K (-0.08 %) |
Mar 02 2016 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 40.39 | 23,240 | 938,696 | 895,259 | 918.5 K to 895.3 K (-2.53 %) |
Feb 19 2016 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 35.21 | 200 | 7,042 | 63,683 | 63.9 K to 63.7 K (-0.31 %) |
Feb 19 2016 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 34.45 | 3,000 | 103,347 | 63,883 | 66.9 K to 63.9 K (-4.49 %) |
Feb 04 2016 | JUNO | Juno Therapeutics, ... | Levitsky Hyam | See Remarks | Option Exercise | A | 24.50 | 100,000 | 2,450,000 | 100,000 | |
Feb 04 2016 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Option Exercise | A | 24.50 | 75,000 | 1,837,500 | 75,000 | |
Feb 04 2016 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO and President | Option Exercise | A | 24.50 | 200,000 | 4,900,000 | 200,000 | |
Feb 04 2016 | JUNO | Juno Therapeutics, ... | Harr Steve | See Remarks | Option Exercise | A | 24.50 | 155,000 | 3,797,500 | 155,000 | |
Feb 04 2016 | JUNO | Juno Therapeutics, ... | Frohlich Mark W | See Remarks | Option Exercise | A | 24.50 | 55,000 | 1,347,500 | 55,000 | |
Apr 19 2016 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 43.51 | 1,993 | 86,707 | 870,799 | 872.8 K to 870.8 K (-0.23 %) |
Apr 19 2016 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 42.79 | 10,007 | 428,150 | 872,792 | 882.8 K to 872.8 K (-1.13 %) |
Apr 19 2016 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Sell | S | 43.60 | 650 | 28,342 | 57,283 | 57.9 K to 57.3 K (-1.12 %) |
Apr 19 2016 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Sell | S | 43.00 | 2,550 | 109,657 | 57,933 | 60.5 K to 57.9 K (-4.22 %) |
Jan 20 2016 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 34.12 | 800 | 27,296 | 66,883 | 67.7 K to 66.9 K (-1.18 %) |
Jan 20 2016 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 33.37 | 2,400 | 80,077 | 67,683 | 70.1 K to 67.7 K (-3.42 %) |
Dec 21 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 45.92 | 1,310 | 60,151 | 70,083 | 71.4 K to 70.1 K (-1.83 %) |
Dec 21 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 45.02 | 1,890 | 85,084 | 71,393 | 73.3 K to 71.4 K (-2.58 %) |
Dec 18 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Gift | G | 0.00 | 10,000 | 0 | 65,000 | 75 K to 65 K (-13.33 %) |
Dec 17 2015 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 46.62 | 4,085 | 190,459 | 918,499 | 922.6 K to 918.5 K (-0.44 %) |
Dec 17 2015 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 45.74 | 3,700 | 169,236 | 922,584 | 926.3 K to 922.6 K (-0.40 %) |
Dec 17 2015 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 44.81 | 4,215 | 188,866 | 926,284 | 930.5 K to 926.3 K (-0.45 %) |
Dec 17 2015 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO and President | Option Exercise | M | 6.36 | 54,000 | 343,440 | 947,506 | |
Dec 17 2015 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO and President | Sell | S | 46.64 | 31,255 | 1,457,761 | 2,687,359 | 2.7 M to 2.7 M (-1.15 %) |
Dec 17 2015 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO and President | Sell | S | 45.73 | 29,404 | 1,344,760 | 2,718,614 | 2.7 M to 2.7 M (-1.07 %) |
Dec 17 2015 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO and President | Sell | S | 44.77 | 30,841 | 1,380,890 | 2,748,018 | 2.8 M to 2.7 M (-1.11 %) |
Dec 17 2015 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO and President | Buy | M | 6.36 | 54,000 | 343,440 | 2,778,859 | 2.7 M to 2.8 M (+1.98 %) |
Dec 11 2015 | JUNO | Juno Therapeutics, ... | Harr Steve | See Remarks | Sell | S | 46.90 | 3,600 | 168,824 | 765,000 | 768.6 K to 765 K (-0.47 %) |
Dec 11 2015 | JUNO | Juno Therapeutics, ... | Harr Steve | See Remarks | Sell | S | 46.38 | 31,400 | 1,456,250 | 768,600 | 800 K to 768.6 K (-3.92 %) |
Nov 20 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 53.56 | 305 | 16,335 | 71,200 | 71.5 K to 71.2 K (-0.43 %) |
Nov 20 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 52.91 | 2,895 | 153,165 | 71,505 | 74.4 K to 71.5 K (-3.89 %) |
Nov 13 2015 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 50.18 | 500 | 25,091 | 930,499 | 931 K to 930.5 K (-0.05 %) |
Nov 13 2015 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 49.48 | 11,500 | 568,987 | 930,999 | 942.5 K to 931 K (-1.22 %) |
Nov 02 2015 | JUNO | Juno Therapeutics, ... | Azelby Robert | See Remarks | Option Exercise | A | 51.76 | 200,000 | 10,352,000 | 200,000 | |
Nov 02 2015 | JUNO | Juno Therapeutics, ... | Azelby Robert | See Remarks | Grant | A | 0.00 | 38,640 | 0 | 38,640 | 0 to 38.6 K |
Oct 19 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 50.17 | 1,836 | 92,115 | 74,400 | 76.2 K to 74.4 K (-2.41 %) |
Oct 19 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 49.42 | 1,364 | 67,404 | 76,236 | 77.6 K to 76.2 K (-1.76 %) |
Oct 16 2015 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 50.00 | 8,000 | 400,000 | 942,499 | 950.5 K to 942.5 K (-0.84 %) |
Oct 13 2015 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 50.00 | 16,000 | 800,008 | 950,499 | 966.5 K to 950.5 K (-1.66 %) |
Sep 18 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 43.08 | 3,020 | 130,097 | 77,600 | 80.6 K to 77.6 K (-3.75 %) |
Sep 18 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 42.30 | 8,830 | 373,532 | 80,620 | 89.5 K to 80.6 K (-9.87 %) |
Aug 20 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 40.76 | 1,400 | 57,060 | 89,450 | 90.9 K to 89.5 K (-1.54 %) |
Aug 20 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 40.06 | 10,450 | 418,673 | 90,850 | 101.3 K to 90.9 K (-10.32 %) |
Jul 29 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 47.82 | 146,614 | 7,011,081 | 0 | 146.6 K to 0 (-100.00 %) |
Jul 29 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 48.26 | 80,740 | 3,896,512 | 146,614 | 227.4 K to 146.6 K (-35.51 %) |
Jul 17 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 51.12 | 1,650 | 84,344 | 101,300 | 103 K to 101.3 K (-1.60 %) |
Jul 17 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 50.45 | 10,200 | 514,633 | 102,950 | 113.2 K to 103 K (-9.01 %) |
Jul 17 2015 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 53.94 | 117 | 6,311 | 966,499 | 966.6 K to 966.5 K (-0.01 %) |
Jul 17 2015 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 53.33 | 7,883 | 420,415 | 966,616 | 974.5 K to 966.6 K (-0.81 %) |
Jul 02 2015 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Sell | S | 54.75 | 40,000 | 2,190,000 | 182,669 | 222.7 K to 182.7 K (-17.96 %) |
Jun 29 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 48.31 | 31,225 | 1,508,480 | 583,333 | 614.6 K to 583.3 K (-5.08 %) |
Jun 29 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 47.55 | 78,395 | 3,727,682 | 614,558 | 693 K to 614.6 K (-11.31 %) |
Jun 29 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 46.57 | 173,713 | 8,089,814 | 692,953 | 866.7 K to 693 K (-20.04 %) |
Jun 29 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 50.99 | 1,800 | 91,782 | 866,666 | 868.5 K to 866.7 K (-0.21 %) |
Jun 29 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 50.26 | 85,800 | 4,312,308 | 868,466 | 954.3 K to 868.5 K (-8.99 %) |
Jun 29 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 49.19 | 71,725 | 3,528,153 | 954,266 | 1 M to 954.3 K (-6.99 %) |
Jun 29 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 48.39 | 140,675 | 6,807,263 | 1,025,991 | 1.2 M to 1 M (-12.06 %) |
Jun 25 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 51.83 | 2,295 | 118,939 | 113,150 | 115.4 K to 113.2 K (-1.99 %) |
Jun 25 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Sell | S | 51.22 | 9,555 | 489,397 | 115,445 | 125 K to 115.4 K (-7.64 %) |
Jun 25 2015 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 52.77 | 3,101 | 163,639 | 974,499 | 977.6 K to 974.5 K (-0.32 %) |
Jun 25 2015 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 51.98 | 4,899 | 254,663 | 977,600 | 982.5 K to 977.6 K (-0.50 %) |
Jun 25 2015 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Sell | S | 51.33 | 135,000 | 6,929,550 | 222,669 | 357.7 K to 222.7 K (-37.74 %) |
Jun 25 2015 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Sell | S | 50.92 | 135,000 | 6,874,200 | 357,669 | 492.7 K to 357.7 K (-27.40 %) |
Jun 25 2015 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Sell | J | 0.00 | 825,726 | 0 | 492,669 | 1.3 M to 492.7 K (-62.63 %) |
Jun 19 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 53.58 | 50,269 | 2,693,413 | 1,166,666 | 1.2 M to 1.2 M (-4.13 %) |
Jun 19 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 52.74 | 154,495 | 8,148,066 | 1,216,935 | 1.4 M to 1.2 M (-11.27 %) |
Jun 19 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 52.07 | 78,569 | 4,091,088 | 1,371,430 | 1.4 M to 1.4 M (-5.42 %) |
Jun 19 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 56.32 | 12,000 | 675,840 | 1,449,999 | 1.5 M to 1.4 M (-0.82 %) |
Jun 19 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 55.85 | 11,602 | 647,972 | 1,461,999 | 1.5 M to 1.5 M (-0.79 %) |
Jun 19 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 54.70 | 28,603 | 1,564,584 | 1,473,601 | 1.5 M to 1.5 M (-1.90 %) |
Jun 19 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 53.84 | 63,574 | 3,422,824 | 1,502,204 | 1.6 M to 1.5 M (-4.06 %) |
Jun 19 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 52.65 | 94,080 | 4,953,312 | 1,565,778 | 1.7 M to 1.6 M (-5.67 %) |
Jun 19 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Sell | S | 51.59 | 90,141 | 4,650,374 | 1,659,858 | 1.7 M to 1.7 M (-5.15 %) |
Jun 16 2015 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Option Exercise | A | 60.00 | 12,000 | 720,000 | 12,000 | |
Jun 16 2015 | JUNO | Juno Therapeutics, ... | PIEN HOWARD H | Director | Option Exercise | A | 60.00 | 12,000 | 720,000 | 12,000 | |
Jun 16 2015 | JUNO | Juno Therapeutics, ... | Wilderotter Mary Agnes | Director | Option Exercise | A | 60.00 | 12,000 | 720,000 | 12,000 | |
Jun 16 2015 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Option Exercise | A | 60.00 | 12,000 | 720,000 | 12,000 | |
Jun 16 2015 | JUNO | Juno Therapeutics, ... | Barron Hal | Director | Option Exercise | A | 60.00 | 12,000 | 720,000 | 12,000 | |
Jun 16 2015 | JUNO | Juno Therapeutics, ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 60.00 | 12,000 | 720,000 | 12,000 | |
Jun 16 2015 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Option Exercise | A | 60.00 | 12,000 | 720,000 | 12,000 | |
Jun 01 2015 | JUNO | Juno Therapeutics, ... | Levitsky Hyam | See Remarks | Option Exercise | A | 50.60 | 175,000 | 8,855,000 | 175,000 | |
Jun 01 2015 | JUNO | Juno Therapeutics, ... | Levitsky Hyam | See Remarks | Grant | A | 0.00 | 145,000 | 0 | 145,000 | 0 to 145 K |
Mar 05 2015 | JUNO | Juno Therapeutics, ... | Frohlich Mark W | See Remarks | Option Exercise | A | 48.06 | 50,500 | 2,427,030 | 50,500 | |
Mar 05 2015 | JUNO | Juno Therapeutics, ... | Harr Steve | See Remarks | Option Exercise | A | 48.06 | 70,000 | 3,364,200 | 70,000 | |
Mar 05 2015 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | See Remarks | Option Exercise | A | 48.06 | 140,000 | 6,728,400 | 140,000 | |
Mar 05 2015 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Option Exercise | A | 48.06 | 50,500 | 2,427,030 | 50,500 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | PIEN HOWARD H | Director | Option Exercise | C | 0.00 | 75,000 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | PIEN HOWARD H | Director | Buy | C | 0.00 | 75,000 | 0 | 150,000 | 75 K to 150 K (+100.00 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Option Exercise | C | 0.00 | 457,875 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Option Exercise | C | 0.00 | 3,747,500 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Option Exercise | C | 0.00 | 6,250,000 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Buy | C | 0.00 | 457,875 | 0 | 11,552,390 | 11.1 M to 11.6 M (+4.13 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Buy | C | 0.00 | 3,747,500 | 0 | 11,094,515 | 7.3 M to 11.1 M (+51.01 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Buy | C | 0.00 | 6,250,000 | 0 | 7,347,015 | 1.1 M to 7.3 M (+569.73 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Option Exercise | C | 0.00 | 68,395 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Option Exercise | C | 0.00 | 1,250,000 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Option Exercise | C | 0.00 | 2,277,732 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Option Exercise | C | 0.00 | 8,750,000 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Option Exercise | C | 0.00 | 13,750,000 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Buy | C | 0.00 | 68,395 | 0 | 1,318,395 | 1.3 M to 1.3 M (+5.47 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Buy | C | 0.00 | 1,250,000 | 0 | 1,250,000 | 0 to 1.3 M |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Buy | C | 0.00 | 2,277,732 | 0 | 25,766,130 | 23.5 M to 25.8 M (+9.70 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Buy | C | 0.00 | 8,750,000 | 0 | 23,488,398 | 14.7 M to 23.5 M (+59.37 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Buy | C | 0.00 | 13,750,000 | 0 | 14,738,398 | 988.4 K to 14.7 M (+1,391.14 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | BRATTON DOUGLAS K | 10% Owner | Buy | P | 25.00 | 625,000 | 15,625,000 | 988,398 | 363.4 K to 988.4 K (+171.99 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Option Exercise | C | 0.00 | 1,689 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Option Exercise | C | 0.00 | 25,000 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Buy | C | 0.00 | 1,689 | 0 | 26,689 | 25 K to 26.7 K (+6.76 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel and ... | Buy | C | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Option Exercise | C | 0.00 | 1,749,999 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Buy | C | 0.00 | 1,749,999 | 0 | 1,749,999 | 0 to 1.7 M |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Arch Venture Fund VII LP | 10% Owner | Option Exercise | C | 0.00 | 457,875 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Arch Venture Fund VII LP | 10% Owner | Option Exercise | C | 0.00 | 3,747,500 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Arch Venture Fund VII LP | 10% Owner | Option Exercise | C | 0.00 | 6,250,000 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Arch Venture Fund VII LP | 10% Owner | Buy | C | 0.00 | 457,875 | 0 | 11,552,390 | 11.1 M to 11.6 M (+4.13 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Arch Venture Fund VII LP | 10% Owner | Buy | C | 0.00 | 3,747,500 | 0 | 11,094,515 | 7.3 M to 11.1 M (+51.01 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Arch Venture Fund VII LP | 10% Owner | Buy | C | 0.00 | 6,250,000 | 0 | 7,347,015 | 1.1 M to 7.3 M (+569.73 %) |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Barron Hal | Director | Buy | P | 24.00 | 100,000 | 2,400,000 | 100,000 | 0 to 100 K |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Tessier-Lavigne Marc | Director | Option Exercise | C | 0.00 | 175,000 | 0 | 0 | |
Dec 23 2014 | JUNO | Juno Therapeutics, ... | Tessier-Lavigne Marc | Director | Buy | C | 0.00 | 175,000 | 0 | 250,000 | 75 K to 250 K (+233.33 %) |